<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Enrolled-Bill" dms-id="H6B1F9005D8DC4E2197ACF14DCDC94493" public-private="public" key="H" bill-type="olc" stage-count="1"> 
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title> HR 8454 ENR: Medical Marijuana and Cannabidiol Research Expansion Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date></dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="no">I</distribution-code> 
<congress display="yes">One Hundred Seventeenth Congress of the United States of America</congress><session display="yes">At the Second Session</session><enrolled-dateline>Begun and held at the City of Washington on Monday, the third day of January, two thousand and twenty-two</enrolled-dateline> 
<legis-num display="yes">H. R. 8454</legis-num> 
<current-chamber display="no"></current-chamber> 
<legis-type>AN ACT</legis-type> 
<official-title display="yes">To expand research on cannabidiol and marijuana, and for other purposes.</official-title> 
</form> 
<legis-body id="HF926284E23114DD88154BC51CD5F4438" style="OLC"> 
<section id="HA3D1F07201EF4014B6BD22F5060A15AB" section-type="section-one" commented="no" display-inline="no-display-inline"><enum>1.</enum><header display-inline="yes-display-inline">Short title; table of contents</header> 
<subsection id="HB264483E4BA540B2BA41269D1FB6CB9D" commented="no" display-inline="no-display-inline"><enum>(a)</enum><header display-inline="yes-display-inline">Short title</header><text display-inline="yes-display-inline">This Act may be cited as the <quote><short-title>Medical Marijuana and Cannabidiol Research Expansion Act</short-title></quote>.</text></subsection> <subsection id="H280D836063844730BAF830D8CA6E65AE" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header display-inline="yes-display-inline">Table of contents</header><text display-inline="yes-display-inline">The table of contents for this Act is as follows: </text> 
<toc container-level="legis-body-container" quoted-block="no-quoted-block" lowest-level="section" regeneration="yes-regeneration" lowest-bolded-level="division-lowest-bolded"> 
<toc-entry idref="HA3D1F07201EF4014B6BD22F5060A15AB" level="section">Sec. 1. Short title; table of contents.</toc-entry> 
<toc-entry idref="H41CBAC5AC416494D8110D505BAB9A141" level="section">Sec. 2. Definitions.</toc-entry> 
<toc-entry idref="HE03288F1531B47E1846ADB7F11A45E20" level="section">Sec. 3. Determination of budgetary effects.</toc-entry> 
<toc-entry idref="HD5E574F8658E4FD695A8FC6D6E399224" level="title">Title I—Registrations for marijuana research</toc-entry> 
<toc-entry idref="H2BF5872350EA4EF6B285F78739733B4D" level="section">Sec. 101. Marijuana research applications.</toc-entry> 
<toc-entry idref="H735ADB2FE1F34672A469A41F55B5DF2E" level="section">Sec. 102. Research protocols.</toc-entry> 
<toc-entry idref="H48E18EAE16724A2AAD2C4A9A9B95BEED" level="section">Sec. 103. Applications to manufacture marijuana for research.</toc-entry> 
<toc-entry idref="HB5A840D1432C4CBBB3B01E5FB893D84A" level="section">Sec. 104. Adequate and uninterrupted supply.</toc-entry> 
<toc-entry idref="HD8C9E49D815D4BE1B4035108196C2451" level="section">Sec. 105. Security requirements.</toc-entry> 
<toc-entry idref="H26C3DD7C20734446BEC31733A4DA14B0" level="section">Sec. 106. Prohibition against reinstating interdisciplinary review process for non-NIH-funded researchers.</toc-entry> 
<toc-entry idref="HD1D607D15407420EB09F3831DF060157" level="title">Title II—Development of FDA-approved drugs using cannabidiol and marijuana</toc-entry> 
<toc-entry idref="HF0E35C75578040C6A4473FDE9DB5D610" level="section">Sec. 201. Medical research on cannabidiol.</toc-entry> 
<toc-entry idref="HD6D57EC81C054BF0877A60456D8F9298" level="section">Sec. 202. Registration for the commercial production and distribution of Food and Drug Administration-approved drugs.</toc-entry> 
<toc-entry idref="H1A00A3642F3B4CB7B4CACFA75BADB000" level="title">Title III—Doctor-patient relationship</toc-entry> 
<toc-entry idref="HCB35A842437E4E409D377F3F7EC66516" level="section">Sec. 301. Doctor-patient relationship.</toc-entry> 
<toc-entry idref="H78C6A35E0EB9450C8D21B707E303F36D" level="title">Title IV—Federal research</toc-entry> 
<toc-entry idref="HC2B7155C8C71465497F382751AB40CCA" level="section">Sec. 401. Federal research.</toc-entry> </toc></subsection></section> 
<section id="H41CBAC5AC416494D8110D505BAB9A141" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>2.</enum><header display-inline="yes-display-inline">Definitions</header> 
<subsection id="H9D53D9D8D1C246E9A3890A8E619F766D"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">In this Act—</text> <paragraph id="H35BD05C9EA6845A4A21E83007B1D5163" commented="no" display-inline="no-display-inline"><enum>(1)</enum><text display-inline="yes-display-inline">the term <term>appropriately registered</term> means that an individual or entity is registered under the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>) to engage in the type of activity that is carried out by the individual or entity with respect to a controlled substance on the schedule that is applicable to cannabidiol or marijuana, as applicable;</text></paragraph> 
<paragraph id="H327F5AC1F82E48D09F14A2D29BCE47DF" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">the term <term>cannabidiol</term> means—</text> <subparagraph id="HAE7DDEC4F6B4450DB9BA8B2F88E1F8BB" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">the substance, cannabidiol, as derived from marijuana that has a delta-9-tetrahydrocannabinol level that is greater than 0.3 percent; and</text></subparagraph> 
<subparagraph id="HAC1B578B204A48058234A6DAE2BAD372" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">the synthetic equivalent of the substance described in subparagraph (A);</text></subparagraph></paragraph> <paragraph commented="no" display-inline="no-display-inline" id="HADF1977A4F21481F88FA048885D3060A"><enum>(3)</enum><text display-inline="yes-display-inline">the terms <term>controlled substance</term>, <term>dispense</term>, <term>distribute</term>, <term>manufacture</term>, <term>marijuana</term>, and <term>practitioner</term> have the meanings given such terms in section 102 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>), as amended by this Act;</text></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HDED50486C94449949D8761AB47553FC3"><enum>(4)</enum><text display-inline="yes-display-inline">the term <term>covered institution of higher education</term> means an institution of higher education (as defined in section 101 of the Higher Education Act of 1965 (<external-xref legal-doc="usc" parsable-cite="usc/20/1001">20 U.S.C. 1001</external-xref>)) that—</text> <subparagraph commented="no" display-inline="no-display-inline" id="H739CE93DB52A4A93A8FFF31A63E7FDA7"><enum>(A)</enum> <clause commented="no" display-inline="yes-display-inline" id="H521707F2951244DC910794290095509B"><enum>(i)</enum><text display-inline="yes-display-inline">has highest or higher research activity, as defined by the Carnegie Classification of Institutions of Higher Education; or</text></clause> 
<clause commented="no" display-inline="no-display-inline" id="H2AAD9D4F4F984F7792E23F108FACB81C" indent="up1"><enum>(ii)</enum><text display-inline="yes-display-inline">is an accredited medical school or an accredited school of osteopathic medicine; and</text></clause></subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="HDDA76910BFE84DB4A92CB6D990B6E345"><enum>(B)</enum><text display-inline="yes-display-inline">is appropriately registered under the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>);</text></subparagraph></paragraph> 
<paragraph id="HB99DEAEBEE4A42B9B3F12B08BFC227FC" commented="no" display-inline="no-display-inline"><enum>(5)</enum><text display-inline="yes-display-inline">the term <term>drug</term> has the meaning given the term in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(g)(1)</external-xref>);</text></paragraph> <paragraph id="H30EE944DE7EA4F9A800C692DB55D6C98" commented="no" display-inline="no-display-inline"><enum>(6)</enum><text display-inline="yes-display-inline">the term <term>medical research for drug development</term> means medical research that is—</text> 
<subparagraph id="HBAE9E21C6AEE48EAA4CAB3EE457CC9B9" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">a preclinical study or clinical investigation conducted in accordance with section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>) or otherwise permitted by the Department of Health and Human Services to determine the potential medical benefits of marijuana or cannabidiol as a drug; and</text></subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="H2E039CB1AFB64083820B180A14CD5C80"><enum>(B)</enum><text display-inline="yes-display-inline">conducted by a covered institution of higher education, practitioner, or manufacturer that is appropriately registered under the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>); and</text></subparagraph></paragraph> 
<paragraph commented="no" display-inline="no-display-inline" id="HB6CB0C166D124E64A225903F5A390CC2"><enum>(7)</enum><text display-inline="yes-display-inline">the term <term>State</term> means any State of the United States, the District of Columbia, and any territory of the United States.</text></paragraph></subsection> <subsection id="H5AC1808C1AF14F62A4C2143F62D20567"><enum>(b)</enum><header>Updating term</header><text display-inline="yes-display-inline">Section 102(16) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802(16)</external-xref>) is amended—</text> 
<paragraph id="HA77BB84514114EB38F47AF0BFDCE72FE"><enum>(1)</enum><text>in subparagraph (A), by striking <quote>the term <term>marihuana</term> means</quote> and inserting <quote>the terms <term>marihuana</term> and <term>marijuana</term> mean</quote>; and</text></paragraph> <paragraph id="H65DD1E2540A445628BFC954E84FDEED6"><enum>(2)</enum><text>in subparagraph (B), by striking <quote>The term <term>marihuana</term> does not</quote> and inserting <quote>The terms <term>marihuana</term> and <term>marijuana</term> do not</quote>.</text></paragraph></subsection></section> 
<section id="HE03288F1531B47E1846ADB7F11A45E20"><enum>3.</enum><header>Determination of budgetary effects</header><text display-inline="no-display-inline">The budgetary effects of this Act, for the purpose of complying with the Statutory Pay-As-You-Go Act of 2010, shall be determined by reference to the latest statement titled <quote>Budgetary Effects of PAYGO Legislation</quote> for this Act, submitted for printing in the Congressional Record by the Chairman of the House Budget Committee, provided that such statement has been submitted prior to the vote on passage.</text></section> <title id="HD5E574F8658E4FD695A8FC6D6E399224" style="OLC" commented="no" level-type="subsequent"><enum>I</enum><header display-inline="yes-display-inline">Registrations for marijuana research</header> <section id="H2BF5872350EA4EF6B285F78739733B4D" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>101.</enum><header display-inline="yes-display-inline">Marijuana research applications</header><text display-inline="no-display-inline">Section 303(f) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(f)</external-xref>) is amended—</text> 
<paragraph id="H6A74C2D6B9B248838D2A576AFB985544" commented="no" display-inline="no-display-inline"><enum>(1)</enum><text display-inline="yes-display-inline">by redesignating paragraphs (1) through (5) as subparagraphs (A) through (E), respectively;</text></paragraph> <paragraph id="HF9AF183938244093880BB43EA7519C28" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">by striking <quote>(f) The Attorney General</quote> and inserting <quote>(f)(1) The Attorney General</quote>;</text></paragraph> 
<paragraph id="H52C3FFECEE1B4CF4B3FC0BD20E7C5746" commented="no" display-inline="no-display-inline"><enum>(3)</enum><text display-inline="yes-display-inline">by striking <quote>Registration applications</quote> and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="H18FC55E108AF4BAFAB261433307BFA27" style="OLC"> <paragraph id="H89B0821991AF49D7A6D7679FE4DC1130" indent="up1" commented="no" display-inline="no-display-inline"><enum>(2)</enum> <subparagraph commented="no" display-inline="yes-display-inline" id="H60AE9788D6714093A9C03CCBF8E7ADD2"><enum>(A)</enum><text display-inline="yes-display-inline">Registration applications</text></subparagraph></paragraph><after-quoted-block display="yes">;</after-quoted-block></quoted-block></paragraph> 
<paragraph id="H75506AD6934A4AF8BC18E75203DF344D" commented="no" display-inline="no-display-inline"><enum>(4)</enum><text display-inline="yes-display-inline">by striking <quote>Article 7</quote> and inserting the following:</text> <quoted-block display-inline="no-display-inline" id="H350315F2CFDD4EBF9C5D100ECA4ED811" style="OLC"> <paragraph id="HF2CC450A533E42F182C72C68DF2F7A2C" indent="up1" commented="no" display-inline="no-display-inline"><enum>(3)</enum><text display-inline="yes-display-inline">Article 7</text></paragraph><after-quoted-block display="yes">; and</after-quoted-block></quoted-block></paragraph> 
<paragraph id="HD6F820F50EE149CD934B3CE761464F0E" commented="no" display-inline="no-display-inline"><enum>(5)</enum><text display-inline="yes-display-inline">by inserting after paragraph (2)(A), as so designated, the following:</text> <quoted-block display-inline="no-display-inline" id="H9926A23450744118B9F3350D4E630D28" style="OLC"> <subparagraph id="HADD2E936C72C4BA29A46403E4196D967" indent="up2" commented="no" display-inline="no-display-inline"><enum>(B)</enum> <clause commented="no" display-inline="yes-display-inline" id="H25568766FED64D65832DB80AAC43C8A0"><enum>(i)</enum><text display-inline="yes-display-inline">The Attorney General shall register a practitioner to conduct research with marijuana (including any derivative, extract, preparation, and compound thereof) if—</text> 
<subclause id="H2687BC332D2349B19130F1EBB697E685" indent="up1"><enum>(I)</enum><text>the applicant’s research protocol has been reviewed and allowed—</text> <item id="H961D4C200AF44A31A4ED107F6B58ADF0"><enum>(aa)</enum><text display-inline="yes-display-inline">by the Secretary of Health and Human Services under section 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>);</text></item> 
<item id="HB95C1374B0F64EF3ADECE29DC6130969"><enum>(bb)</enum><text>by the National Institutes of Health or another Federal agency that funds scientific research; or</text></item> <item id="H583755ABC5D740FBA636304541BC835F"><enum>(cc)</enum><text>pursuant to sections 1301.18 and 1301.32 of title 21, Code of Federal Regulations, or any successors thereto; and</text> </item></subclause> 
<subclause id="H2FE2E2223B8E47978979794424705F85" indent="up1" commented="no" display-inline="no-display-inline"><enum>(II)</enum><text display-inline="yes-display-inline">the applicant has demonstrated to the Attorney General that there are effective procedures in place to adequately safeguard against diversion of the controlled substance for legitimate medical or scientific use pursuant to section 105 of the <short-title>Medical Marijuana and Cannabidiol Research Expansion Act</short-title>, including demonstrating that the security measures are adequate for storing the quantity of marijuana the applicant would be authorized to possess.</text></subclause></clause> <clause id="HD8D0035BAC8E44AABF5336B0BB2A84C9" indent="up1" commented="no" display-inline="no-display-inline"><enum>(ii)</enum><text display-inline="yes-display-inline">The Attorney General may deny an application for registration under this subparagraph only if the Attorney General determines that the issuance of the registration would be inconsistent with the public interest. In determining the public interest, the Attorney General shall consider the factors listed in—</text> 
<subclause id="H35E94B739FD6440584E9E4A67A23D3A0" commented="no" display-inline="no-display-inline"><enum>(I)</enum><text display-inline="yes-display-inline">subparagraphs (B) through (E) of paragraph (1); and</text></subclause> <subclause id="H5DFB46839EA44FAAB488EDE997E8DD9F" commented="no" display-inline="no-display-inline"><enum>(II)</enum><text display-inline="yes-display-inline">subparagraph (A) of paragraph (1), if the applicable State requires practitioners conducting research to register with a board or authority described in such subparagraph (A).</text></subclause></clause> 
<clause id="H7690B97429C34E7EBEEB2FFAD9C3B6FB" indent="up1" commented="no" display-inline="no-display-inline"><enum>(iii)</enum> 
<subclause commented="no" display-inline="yes-display-inline" id="H1A7A7CFDA9BB403D829A2757AEAA424C"><enum>(I)</enum><text display-inline="yes-display-inline">Not later than 60 days after the date on which the Attorney General receives a complete application for registration under this subparagraph, the Attorney General shall—</text> <item id="HA2BE640F197B4EEBB0B886ECA7691307" indent="up1" commented="no" display-inline="no-display-inline"><enum>(aa)</enum><text display-inline="yes-display-inline">approve the application; or</text></item> 
<item id="HBEDE54EB904C457CA4F89FBE0BC93147" indent="up1" commented="no" display-inline="no-display-inline"><enum>(bb)</enum><text display-inline="yes-display-inline">request supplemental information.</text></item></subclause> <subclause id="HA7675404567B43D68C85B1D76B5CBEF7" indent="up1" commented="no" display-inline="no-display-inline"><enum>(II)</enum><text display-inline="yes-display-inline">For purposes of subclause (I), an application shall be deemed complete when the applicant has submitted documentation showing that the requirements under clause (i) are satisfied.</text></subclause></clause> 
<clause id="H2CB8141DE3944D40B39B17E001EB40D4" indent="up1" commented="no" display-inline="no-display-inline"><enum>(iv)</enum><text display-inline="yes-display-inline">Not later than 30 days after the date on which the Attorney General receives supplemental information as described in clause (iii)(I)(bb) in connection with an application described in this subparagraph, the Attorney General shall approve or deny the application.</text></clause> <clause id="H552BA2583979489FA3AA8E4FA4B84D30" indent="up1" commented="no" display-inline="no-display-inline"><enum>(v)</enum><text display-inline="yes-display-inline">If an application described in this subparagraph is denied, the Attorney General shall provide a written explanation of the basis of denial to the applicant.</text></clause></subparagraph><after-quoted-block display="yes">.</after-quoted-block></quoted-block></paragraph></section> 
<section id="H735ADB2FE1F34672A469A41F55B5DF2E" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>102.</enum><header display-inline="yes-display-inline">Research protocols</header> 
<subsection id="H11948085FA2C40FC8F1E311C717831C5" commented="no" display-inline="no-display-inline"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Paragraph (2)(B) of section 303(f) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(f)</external-xref>), as added by section 101 of this Act, is further amended by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H3B3B52504C3244AC8F7D9B290C4F4055" style="OLC"> <clause id="H0B31B268FC2849B691823FF44D03F878" indent="up3" commented="no" display-inline="no-display-inline"><enum>(vi)</enum> <subclause commented="no" display-inline="yes-display-inline" id="H7A24ADAF1961433492FC3E843EB7A945"><enum>(I)</enum><text display-inline="yes-display-inline">If the Attorney General grants an application for registration under clause (i), the registrant may amend or supplement the research protocol without notification to, or review by, the Drug Enforcement Administration if the registrant does not change—</text> 
<item id="H3699B30ACCEB46039285BF6F5B74895B" indent="up1" commented="no" display-inline="no-display-inline"><enum>(aa)</enum><text display-inline="yes-display-inline">the quantity or type of marijuana or cannabidiol (including any derivative, extract, preparation, and compound thereof);</text> </item> <item id="H2A8363A68DCD4D7BAA69AA3446011EA4" indent="up1" commented="no" display-inline="no-display-inline"><enum>(bb)</enum><text display-inline="yes-display-inline">the source of such marijuana or cannabidiol; or</text></item> 
<item id="H08E424E860A74D9CB283EE62B4881301" indent="up1" commented="no" display-inline="no-display-inline"><enum>(cc)</enum><text display-inline="yes-display-inline">the conditions under which such marijuana or cannabidiol is stored, tracked, or administered.</text></item></subclause> <subclause id="HEA3F6B582D60416C8AA75F55328119F5" indent="up1" commented="no" display-inline="no-display-inline"><enum>(II)</enum> <item commented="no" display-inline="yes-display-inline" id="HA68C460883864365992C41317F4A532B"><enum>(aa)</enum><text display-inline="yes-display-inline">If a registrant under clause (i) seeks to change the type of marijuana or cannabidiol (including any derivative, extract, preparation, and compound thereof), the source of such marijuana or cannabidiol, or the conditions under which such marijuana or cannabidiol is stored, tracked, or administered, the registrant shall notify the Attorney General via registered mail, or an electronic means permitted by the Attorney General, not later than 30 days before implementing an amended or supplemental research protocol.</text></item> 
<item id="HF12C84330CFC4A16BABD479ED7930C12" indent="up1" commented="no" display-inline="no-display-inline"><enum>(bb)</enum><text display-inline="yes-display-inline">A registrant may proceed with an amended or supplemental research protocol described in item (aa) if the Attorney General does not explicitly object during the 30-day period beginning on the date on which the Attorney General receives the notice under item (aa).</text></item> <item id="HA58F2B4CC6294991B0EF8046BB7DC53F" indent="up1" commented="no" display-inline="no-display-inline"><enum>(cc)</enum><text display-inline="yes-display-inline">The Attorney General may only object to an amended or supplemental research protocol under this subclause if additional security measures are needed to safeguard against diversion or abuse.</text></item> 
<item id="H862661ADC5F0493081FB754C9EB9B486" indent="up1" commented="no" display-inline="no-display-inline"><enum>(dd)</enum><text display-inline="yes-display-inline">If a registrant under clause (i) seeks to address additional security measures identified by the Attorney General under item (cc), the registrant shall notify the Attorney General via registered mail, or an electronic means permitted by the Attorney General, not later than 30 days before implementing an amended or supplemental research protocol.</text></item> <item id="HD82F21B3C76F4C43A1E9987D1C7C847F" indent="up1" commented="no" display-inline="no-display-inline"><enum>(ee)</enum><text display-inline="yes-display-inline">A registrant may proceed with an amended or supplemental research protocol described in item (dd) if the Attorney General does not explicitly object during the 30-day period beginning on the date on which the Attorney General receives the notice under item (dd).</text></item></subclause> 
<subclause id="HC45A3F0772F94C43AE2AB9197424DC3D" indent="up1" commented="no" display-inline="no-display-inline"><enum>(III)</enum> 
<item commented="no" display-inline="yes-display-inline" id="HE46100339F7A4092BED6B98B6FC47ED6"><enum>(aa)</enum><text display-inline="yes-display-inline">If a registrant under clause (i) seeks to change the quantity of marijuana needed for research and the change in quantity does not impact the factors described in item (bb) or (cc) of subclause (I) of this clause, the registrant shall notify the Attorney General via registered mail or using an electronic means permitted by the Attorney General.</text></item> <item id="HB6E5C9478D8442439584F8608C4D8037" indent="up1" commented="no" display-inline="no-display-inline"><enum>(bb)</enum><text display-inline="yes-display-inline">A notification under item (aa) shall include—</text> 
<subitem id="H66A5CBF64E5F4D7E84FC36151001C667" commented="no" display-inline="no-display-inline"><enum>(AA)</enum><text display-inline="yes-display-inline">the Drug Enforcement Administration registration number of the registrant;</text></subitem> <subitem id="H57D667FB178D4D0D84AB71629E5CBA2D" commented="no" display-inline="no-display-inline"><enum>(BB)</enum><text display-inline="yes-display-inline">the quantity of marijuana or cannabidiol already obtained;</text></subitem> 
<subitem id="HF37BD8384A544647904D6A400DAFC27B" commented="no" display-inline="no-display-inline"><enum>(CC)</enum><text display-inline="yes-display-inline">the quantity of additional marijuana or cannabidiol needed to complete the research; and</text></subitem> <subitem id="HC4503481FE6C4CB58BFE2FAD80E3E5D3" commented="no" display-inline="no-display-inline"><enum>(DD)</enum><text display-inline="yes-display-inline">an attestation that the change in quantity does not impact the source of the marijuana or cannabidiol or the conditions under which the marijuana or cannabidiol is stored, tracked, or administered.</text></subitem></item> 
<item id="H2E45115212EB4346A894FB8C9E1B3AF9" indent="up1" commented="no" display-inline="no-display-inline"><enum>(cc)</enum><text display-inline="yes-display-inline">The Attorney General shall ensure that—</text> <subitem id="HA88E21828BBA45D888FDA0166B25A2AF" commented="no" display-inline="no-display-inline"><enum>(AA)</enum><text display-inline="yes-display-inline">any registered mail return receipt with respect to a notification under item (aa) is submitted for delivery to the registrant providing the notification not later than 3 days after receipt of the notification by the Attorney General; and</text></subitem> 
<subitem id="HE20675136B824C839794F89B2F86342D" commented="no" display-inline="no-display-inline"><enum>(BB)</enum><text display-inline="yes-display-inline">notice of receipt of a notification using an electronic means permitted under item (aa) is provided to the registrant providing the notification not later than 3 days after receipt of the notification by the Attorney General.</text></subitem></item> <item id="HB47F4F4CE59A40548BDA2890ABA79B44" indent="up1" commented="no" display-inline="no-display-inline"><enum>(dd)</enum> <subitem commented="no" display-inline="yes-display-inline" id="H50C6FA928B684F93A2FA3DCD268DE8AA"><enum>(AA)</enum><text display-inline="yes-display-inline">On and after the date described in subitem (BB), a registrant that submits a notification in accordance with item (aa) may proceed with the research as if the change in quantity has been approved on such date, unless the Attorney General notifies the registrant of an objection described in item (ee).</text></subitem> 
<subitem id="HBE98B8688C134909B1CAB2C23C903414" indent="up1" commented="no" display-inline="no-display-inline"><enum>(BB)</enum><text display-inline="yes-display-inline">The date described in this subitem is the date on which a registrant submitting a notification under item (aa) receives the registered mail return receipt with respect to the notification or the date on which the registrant receives notice that the notification using an electronic means permitted under item (aa) was received by the Attorney General, as the case may be.</text></subitem></item> <item id="H8400B46310A7454DB5C64088BACBBC92" indent="up1" commented="no" display-inline="no-display-inline"><enum>(ee)</enum><text display-inline="yes-display-inline">A notification submitted under item (aa) shall be deemed to be approved unless the Attorney General, not later than 10 days after receiving the notification, explicitly objects based on a finding that the change in quantity—</text> 
<subitem id="HC4E1D2088FC74063AFC90ECB03E68B02" commented="no" display-inline="no-display-inline"><enum>(AA)</enum><text display-inline="yes-display-inline">does impact the source of the marijuana or cannabidiol or the conditions under which the marijuana or cannabidiol is stored, tracked, or administered; or</text></subitem> <subitem id="H5426F2BCA31C4BF59D6A6B93C09A1BE9" commented="no" display-inline="no-display-inline"><enum>(BB)</enum><text display-inline="yes-display-inline">necessitates that the registrant implement additional security measures to safeguard against diversion or abuse.</text></subitem></item></subclause> 
<subclause id="H2C97D56C7D534276B9E51DB246E48667" indent="up1" commented="no" display-inline="no-display-inline"><enum>(IV)</enum><text display-inline="yes-display-inline">Nothing in this clause shall limit the authority of the Secretary of Health and Human Services over requirements related to research protocols, including changes in—</text> <item id="H6C45747CC03E4458B164EDF5B6730AE9" commented="no" display-inline="no-display-inline"><enum>(aa)</enum><text display-inline="yes-display-inline">the method of administration of marijuana or cannabidiol;</text></item> 
<item id="H0B640257015144A3BDC0835CC05CF7AF" commented="no" display-inline="no-display-inline"><enum>(bb)</enum><text display-inline="yes-display-inline">the dosing of marijuana or cannabidiol; and</text></item> <item id="H8F9234489468463396B43C48625CC449" commented="no" display-inline="no-display-inline"><enum>(cc)</enum><text display-inline="yes-display-inline">the number of individuals or patients involved in research.</text></item></subclause></clause><after-quoted-block display="yes">.</after-quoted-block></quoted-block></subsection> 
<subsection id="H7927617A29594602842C5EC0AA65470E" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header display-inline="yes-display-inline">Regulations</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Attorney General shall promulgate regulations to carry out the amendment made by this section.</text></subsection></section> <section id="H48E18EAE16724A2AAD2C4A9A9B95BEED" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>103.</enum><header display-inline="yes-display-inline">Applications to manufacture marijuana for research</header> <subsection id="H966180492FEC4C679FDF0F316027FCC7" commented="no" display-inline="no-display-inline"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>), as amended by sections 101 and 102 of this Act, is further amended—</text> 
<paragraph id="HD29594E2F12E481FBDF9AE276089D9E8" commented="no" display-inline="no-display-inline"><enum>(1)</enum><text display-inline="yes-display-inline">by redesignating subsections (c) through (k) as subsections (d) through (l), respectively;</text></paragraph> <paragraph id="H0C064A25EE754234882876C01E062ED6" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">by inserting after subsection (b) the following:</text> 
<quoted-block display-inline="no-display-inline" id="HF3E4CD18EFA042F8A81AB0FB6FA47C19" style="OLC"> 
<subsection id="HF56761408581458BBD15C740E4947CA8" commented="no" display-inline="no-display-inline"><enum>(c)</enum> 
<paragraph commented="no" display-inline="yes-display-inline" id="HC04BC0676081458CA7DC60F67E37C2E0"><enum>(1)</enum> 
<subparagraph commented="no" display-inline="yes-display-inline" id="H2E428CFBD0FC4E3D9845FDE1EAECFF72"><enum>(A)</enum><text display-inline="yes-display-inline">As it relates to applications to manufacture marijuana for research purposes, when the Attorney General places a notice in the Federal Register to increase the number of entities registered under this Act to manufacture marijuana to supply appropriately registered researchers in the United States, the Attorney General shall, not later than 60 days after the date on which the Attorney General receives a completed application—</text> <clause id="H5F1326F3D5C9477E9C845362EF9C8502" indent="up2" commented="no" display-inline="no-display-inline"><enum>(i)</enum><text display-inline="yes-display-inline">approve the application; or</text></clause> 
<clause id="H970DDF97F3C7448BB7172B09C4FA9122" indent="up2" commented="no" display-inline="no-display-inline"><enum>(ii)</enum><text display-inline="yes-display-inline">request supplemental information.</text></clause></subparagraph> <subparagraph id="H468C7A5513B8456DB5C7338E78AFDE62" indent="up2" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">For purposes of subparagraph (A), an application shall be deemed complete when the applicant has submitted documentation showing each of the following:</text> 
<clause id="H4062EFFB73764C80849F2E76F4525217" commented="no" display-inline="no-display-inline"><enum>(i)</enum><text display-inline="yes-display-inline">The requirements designated in the notice in the Federal Register are satisfied.</text></clause> <clause id="H2673A40FDCC4435CAB89C38E13DF40AF" commented="no" display-inline="no-display-inline"><enum>(ii)</enum><text display-inline="yes-display-inline">The requirements under this Act are satisfied.</text></clause> 
<clause id="HDE707B32356F40F994ABBB1B6B91791A" commented="no" display-inline="no-display-inline"><enum>(iii)</enum><text display-inline="yes-display-inline">The applicant will limit the transfer and sale of any marijuana manufactured under this subsection—</text> <subclause id="HE1FF0A23B181495784CAE42F832C2137" commented="no" display-inline="no-display-inline"><enum>(I)</enum><text display-inline="yes-display-inline">to researchers who are registered under this Act to conduct research with controlled substances in schedule I; and</text></subclause> 
<subclause id="H5B9EEDB56A5248ABBD56DF38FA119107" commented="no" display-inline="no-display-inline"><enum>(II)</enum><text display-inline="yes-display-inline">for purposes of use in preclinical research or in a clinical investigation pursuant to an investigational new drug exemption under 505(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(i)</external-xref>).</text></subclause></clause> <clause id="HE99CE33E218B494BA807090D0BB8027D" commented="no" display-inline="no-display-inline"><enum>(iv)</enum><text display-inline="yes-display-inline">The applicant will transfer or sell any marijuana manufactured under this subsection only with prior, written consent for the transfer or sale by the Attorney General.</text></clause> 
<clause id="HD9BDD3CC95904EFB9BF3A12209BC5ADC" commented="no" display-inline="no-display-inline"><enum>(v)</enum><text display-inline="yes-display-inline">The applicant has completed the application and review process under subsection (a) for the bulk manufacture of controlled substances in schedule I.</text></clause> <clause id="HF46783AB859642ECB80CAD80605293E8" commented="no" display-inline="no-display-inline"><enum>(vi)</enum><text display-inline="yes-display-inline">The applicant has established and begun operation of a process for storage and handling of controlled substances in schedule I, including for inventory control and monitoring security in accordance with section 105 of the <short-title>Medical Marijuana and Cannabidiol Research Expansion Act</short-title>.</text></clause> 
<clause id="H3930E853D5F2456EBA27C9AD3F1166ED" commented="no" display-inline="no-display-inline"><enum>(vii)</enum><text display-inline="yes-display-inline">The applicant is licensed by each State in which the applicant will conduct operations under this subsection, to manufacture marijuana, if that State requires such a license.</text></clause></subparagraph> <subparagraph commented="no" display-inline="no-display-inline" id="HC61C1EDF084745429C8F33A49270F8E2" indent="up2"><enum>(C)</enum><text display-inline="yes-display-inline">Not later than 30 days after the date on which the Attorney General receives supplemental information requested under subparagraph (A)(ii) with respect to an application, the Attorney General shall approve or deny the application.</text></subparagraph></paragraph> 
<paragraph id="H4CC7A943DC654BE498D30FD77AB177B9" indent="up1" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">If an application described in this subsection is denied, the Attorney General shall provide a written explanation of the basis of denial to the applicant.</text></paragraph></subsection><after-quoted-block display="yes">; </after-quoted-block></quoted-block></paragraph> <paragraph id="H2396977BE7A544079616114902908482" commented="no" display-inline="no-display-inline"><enum>(3)</enum><text display-inline="yes-display-inline">in subsection (h)(2), as so redesignated, by striking <quote>subsection (f)</quote> each place it appears and inserting <quote>subsection (g)</quote>;</text></paragraph> 
<paragraph id="H23BCAA96F61F446EBEF23AE1E4530374" commented="no" display-inline="no-display-inline"><enum>(4)</enum><text display-inline="yes-display-inline">in subsection (j)(1), as so redesignated, by striking <quote>subsection (d)</quote> and inserting <quote>subsection (e)</quote>; and</text></paragraph> <paragraph id="H910B0F61C28243C0A88E05061152E4A8" commented="no" display-inline="no-display-inline"><enum>(5)</enum><text display-inline="yes-display-inline">in subsection (k), as so redesignated, by striking <quote>subsection (f)</quote> each place it appears and inserting <quote>subsection (g)</quote>.</text></paragraph></subsection> 
<subsection id="H3004D000F50E45A89AC1C71EDBE0E3FF" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header display-inline="yes-display-inline">Technical and conforming amendments</header> 
<paragraph id="H7E03235391C740DC9E6E72708B49C47E" commented="no" display-inline="no-display-inline"><enum>(1)</enum><text display-inline="yes-display-inline">The Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>) is amended—</text> <subparagraph id="H460236AD8C58452B8C8BEA9516B60E05" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">in section 102 (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>)—</text> 
<clause id="H08AB660C7D7849CCA7FAEA89F559A5E6" commented="no" display-inline="no-display-inline"><enum>(i)</enum><text display-inline="yes-display-inline">in paragraph (52)(B)—</text> <subclause id="H49CFD49D90DE46B28D8885BEEDB20B2E" commented="no" display-inline="no-display-inline"><enum>(I)</enum><text display-inline="yes-display-inline">by striking <quote>303(f)</quote> each place it appears and inserting <quote>303(g)</quote>; and</text></subclause> 
<subclause id="H1C8487EA6C7348C18B32BFB681B18D70" commented="no" display-inline="no-display-inline"><enum>(II)</enum><text display-inline="yes-display-inline">in clause (i), by striking <quote>(d), or (e)</quote> and inserting <quote>(e), or (f)</quote>; and</text></subclause></clause> <clause id="HC7830AE203894553AF8320B61A6A048C" commented="no" display-inline="no-display-inline"><enum>(ii)</enum><text display-inline="yes-display-inline">in paragraph (54), by striking <quote>303(f)</quote> each place it appears and inserting <quote>303(g)</quote>;</text></clause></subparagraph> 
<subparagraph id="HFB34D8ACB44040428E911D3CE3E294AF" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">in section 302(g)(5)(A)(iii)(I)(bb) (21 U.S.C. 822(g)(5)(A)(iii)(I)(bb)), by striking <quote>303(f)</quote> and inserting <quote>303(g)</quote>; </text></subparagraph> <subparagraph id="H5A92AD61403C4E30ADD1852A99C7F7FE" commented="no" display-inline="no-display-inline"><enum>(C)</enum><text display-inline="yes-display-inline">in section 304 (<external-xref legal-doc="usc" parsable-cite="usc/21/824">21 U.S.C. 824</external-xref>), by striking <quote>303(g)(1)</quote> each place it appears and inserting <quote>303(h)(1)</quote>;</text></subparagraph> 
<subparagraph id="HC94029DF693A4A1F8BBB8587967C1385" commented="no" display-inline="no-display-inline"><enum>(D)</enum><text display-inline="yes-display-inline">in section 307(d)(2) (<external-xref legal-doc="usc" parsable-cite="usc/21/827">21 U.S.C. 827(d)(2)</external-xref>), by striking <quote>303(f)</quote> and inserting <quote>303(g)</quote>;</text></subparagraph> <subparagraph id="HEC11F3E9FD6541999C4BD83C4CF29894" commented="no" display-inline="no-display-inline"><enum>(E)</enum><text display-inline="yes-display-inline">in section 309A(a)(2) (<external-xref legal-doc="usc" parsable-cite="usc/21/829a">21 U.S.C. 829a(a)(2)</external-xref>), in the matter preceding subparagraph (A), by striking <quote>303(g)(2)</quote> and inserting <quote>303(h)(2)</quote>; </text></subparagraph> 
<subparagraph id="H3F83C61906DB406182DF3E7E03A34CE1" commented="no" display-inline="no-display-inline"><enum>(F)</enum><text display-inline="yes-display-inline">in section 311(h) (<external-xref legal-doc="usc" parsable-cite="usc/21/831">21 U.S.C. 831(h)</external-xref>), by striking <quote>303(f)</quote> each place it appears and inserting <quote>303(g)</quote>;</text></subparagraph> <subparagraph id="HFA0617EB6D104845BAA32F978615F169" commented="no" display-inline="no-display-inline"><enum>(G)</enum><text display-inline="yes-display-inline">in section 401(h)(2) (<external-xref legal-doc="usc" parsable-cite="usc/21/841">21 U.S.C. 841(h)(2)</external-xref>), by striking <quote>303(f)</quote> each place it appears and inserting <quote>303(g)</quote>;</text></subparagraph> 
<subparagraph id="H74F7F000B1634A93A0BD451D29004E1D" commented="no" display-inline="no-display-inline"><enum>(H)</enum><text display-inline="yes-display-inline">in section 403(c)(2)(B) (<external-xref legal-doc="usc" parsable-cite="usc/21/843">21 U.S.C. 843(c)(2)(B)</external-xref>), by striking <quote>303(f)</quote> and inserting <quote>303(g)</quote>; and</text></subparagraph> <subparagraph id="H4CC3D4642000416B84E301452628E20F" commented="no" display-inline="no-display-inline"><enum>(I)</enum><text display-inline="yes-display-inline">in section 512(c)(1) (<external-xref legal-doc="usc" parsable-cite="usc/21/882">21 U.S.C. 882(c)(1)</external-xref>) by striking <quote>303(f)</quote> and inserting <quote>303(g)</quote>.</text></subparagraph></paragraph> 
<paragraph id="H52EAABEC53B34D9AAD32AC4F0EF9267F" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">Section 1008(c) of the Controlled Substances Import and Export Act (<external-xref legal-doc="usc" parsable-cite="usc/21/958">21 U.S.C. 958(c)</external-xref>) is amended—</text> <subparagraph id="H11186A8165F84E4E8A25012E6DDF9361" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking <quote>303(d)</quote> and inserting <quote>303(e)</quote>; and</text></subparagraph> 
<subparagraph id="H7D95185CCA3D4E3F8384480FC2804F99" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2)(B), by striking <quote>303(h)</quote> and inserting <quote>303(i)</quote>.</text></subparagraph></paragraph> <paragraph id="H5A6B939BD455461DA9AE3731714BE26E" commented="no" display-inline="no-display-inline"><enum>(3)</enum><text display-inline="yes-display-inline">Title V of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/290aa">42 U.S.C. 290aa et seq.</external-xref>) is amended—</text> 
<subparagraph id="H932BEAC4A2724B829AEFE0366F9166D8" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">in section 520E–4(c) (42 U.S.C. 290bb–36d(c)), by striking <quote>303(g)(2)(B)</quote> and inserting <quote>303(h)(2)(B)</quote>; and</text></subparagraph> <subparagraph id="H88B6F037B7C747C1BE21D4E67B8604D9" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">in section 544(a)(3) (<external-xref legal-doc="usc" parsable-cite="usc/42/290dd-3">42 U.S.C. 290dd–3(a)(3)</external-xref>), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>.</text></subparagraph></paragraph> 
<paragraph id="H4C6A58A0C44647E5ADD95B6BA3CAE6BA" commented="no" display-inline="no-display-inline"><enum>(4)</enum><text display-inline="yes-display-inline">Title XVIII of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395">42 U.S.C. 1395 et seq.</external-xref>) is amended—</text> <subparagraph id="HA6FDD5A759F145979DCD5641DF57A056" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">in section 1833(bb)(3)(B) (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(bb)(3)(B)</external-xref>), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>; </text></subparagraph> 
<subparagraph id="H4118E1C88D904E9FB39904BCCBA29350" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">in section 1834(o)(3)(C)(ii) (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m(o)(3)(C)(ii)</external-xref>), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>; and</text></subparagraph> <subparagraph id="H296C2F47EEF6436B86472020DCEB2F3E" commented="no" display-inline="no-display-inline"><enum>(C)</enum><text display-inline="yes-display-inline">in section 1866F(c)(3)(C) (<external-xref legal-doc="usc" parsable-cite="usc/42/1395cc-6">42 U.S.C. 1395cc–6(c)(3)(C)</external-xref>), by striking <quote>303(g)</quote> and inserting <quote>303(h)</quote>. </text></subparagraph></paragraph> 
<paragraph id="HE89D279A6DC2409E8A0E78DC2533F3F0" commented="no" display-inline="no-display-inline"><enum>(5)</enum><text display-inline="yes-display-inline">Section 1903(aa)(2)(C)(ii) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396b">42 U.S.C. 1396b(aa)(2)(C)(ii)</external-xref>) is amended by striking <quote>303(g)</quote> each place it appears and inserting <quote>303(h)</quote>. </text></paragraph></subsection></section> <section id="HB5A840D1432C4CBBB3B01E5FB893D84A" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>104.</enum><header display-inline="yes-display-inline">Adequate and uninterrupted supply</header> <subsection id="H03A3EBEBB6DC4E318B26B335ECABCFCE"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">On an annual basis, the Attorney General, in consultation with the Secretary of Health and Human Services, shall assess whether there is an adequate and uninterrupted supply of marijuana, including of specific strains, for research purposes.</text></subsection> 
<subsection id="HEFE56F9396584397A8FACEEE2054B4F7"><enum>(b)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">If the Attorney General, in consultation with the Secretary of Health and Human Services, determines there is an inadequate or interrupted supply of marijuana, including of specific strains for research purposes, the Attorney General shall report to Congress within 60 days of the determination on at least—</text> <paragraph id="H1B8C4ABE49264FC5A9A8B638F25979F4"><enum>(1)</enum><text>the factors contributing to the inadequate or interrupted supply of marijuana;</text></paragraph> 
<paragraph id="H6733F560FF034E3091EAB22625D56E65"><enum>(2)</enum><text>expected impacts of the inadequate or interrupted supply on ongoing research protocols; and</text></paragraph> <paragraph id="H567F895CA459470485777A66AF79E0CD"><enum>(3)</enum><text>specific steps the Attorney General will take to restore an adequate and uninterrupted supply of marijuana, including of specific strains, for research purposes.</text></paragraph></subsection></section> 
<section id="HD8C9E49D815D4BE1B4035108196C2451" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>105.</enum><header display-inline="yes-display-inline">Security requirements</header> 
<subsection id="H1C5DE8CCE6254467974E2EC329F1404A" commented="no" display-inline="no-display-inline"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">An individual or entity engaged in researching marijuana or its components shall store it in a securely locked, substantially constructed cabinet.</text></subsection> <subsection id="H02691FE3444F48E0B2C289C0E1F1B0C7" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header display-inline="yes-display-inline">Requirements for other measures</header><text display-inline="yes-display-inline">Any other security measures required by the Attorney General to safeguard against diversion shall be consistent with those required for practitioners conducting research on other controlled substances in schedules I and II in section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>) that have a similar risk of diversion and abuse.</text></subsection></section> 
<section id="H26C3DD7C20734446BEC31733A4DA14B0" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>106.</enum><header display-inline="yes-display-inline">Prohibition against reinstating interdisciplinary review process for non-NIH-funded researchers</header><text display-inline="no-display-inline">The Secretary of Health and Human Services may not—</text> <paragraph id="HBAB9C93A87CD4AC3A822873949F57745" commented="no" display-inline="no-display-inline"><enum>(1)</enum><text display-inline="yes-display-inline">reinstate the Public Health Service interdisciplinary review process described in the guidance entitled <quote>Guidance on Procedures for the Provision of Marijuana for Medical Research</quote> (issued on May 21, 1999); or</text></paragraph> 
<paragraph id="HF080A98C276349D49FAF39B074AECFAA" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">require another review of scientific protocols that is applicable only to research on marijuana or its components.</text></paragraph></section></title> <title id="HD1D607D15407420EB09F3831DF060157" commented="no" level-type="subsequent"><enum>II</enum><header display-inline="yes-display-inline">Development of FDA-approved drugs using cannabidiol and marijuana</header> <section id="HF0E35C75578040C6A4473FDE9DB5D610" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>201.</enum><header display-inline="yes-display-inline">Medical research on cannabidiol</header><text display-inline="no-display-inline">Notwithstanding any provision of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>), the Safe and Drug-Free Schools and Communities Act (<external-xref legal-doc="usc" parsable-cite="usc/20/7101">20 U.S.C. 7101 et seq.</external-xref>), <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/41/81">chapter 81</external-xref> of title 41, United States Code, or any other Federal law, an appropriately registered covered institution of higher education, practitioner, or manufacturer may manufacture, distribute, dispense, or possess marijuana or cannabidiol if the marijuana or cannabidiol is manufactured, distributed, dispensed, or possessed, respectively, for purposes of medical research for drug development or subsequent commercial production in accordance with section 202.</text></section> 
<section id="HD6D57EC81C054BF0877A60456D8F9298" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>202.</enum><header display-inline="yes-display-inline">Registration for the commercial production and distribution of Food and Drug Administration-approved drugs</header><text display-inline="no-display-inline">The Attorney General shall register an applicant to manufacture or distribute cannabidiol or marijuana for the purpose of commercial production of a drug containing or derived from marijuana that is approved by the Secretary of Health and Human Services under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), in accordance with the applicable requirements under subsection (a) or (b) of section 303 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823</external-xref>).</text></section></title> <title id="H1A00A3642F3B4CB7B4CACFA75BADB000" style="OLC" commented="no" level-type="subsequent"><enum>III</enum><header display-inline="yes-display-inline">Doctor-patient relationship</header> <section id="HCB35A842437E4E409D377F3F7EC66516" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>301.</enum><header display-inline="yes-display-inline">Doctor-patient relationship</header><text display-inline="no-display-inline">It shall not be a violation of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>) for a State-licensed physician to discuss—</text> 
<paragraph id="H76ED8B1FB3444BFBA3331D85B5DAACF9" commented="no" display-inline="no-display-inline"><enum>(1)</enum><text display-inline="yes-display-inline">the currently known potential harms and benefits of marijuana derivatives, including cannabidiol, as a treatment with the legal guardian of the patient of the physician if the patient is a child; or</text></paragraph> <paragraph id="HEF973D78C0864F0881AB4E47F7E6FDCE" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">the currently known potential harms and benefits of marijuana and marijuana derivatives, including cannabidiol, as a treatment with the patient or the legal guardian of the patient of the physician if the patient is a legal adult.</text></paragraph></section></title> 
<title id="H78C6A35E0EB9450C8D21B707E303F36D" style="OLC" commented="no" level-type="subsequent"><enum>IV</enum><header display-inline="yes-display-inline">Federal research</header> 
<section id="HC2B7155C8C71465497F382751AB40CCA" commented="no" display-inline="no-display-inline" section-type="subsequent-section"><enum>401.</enum><header display-inline="yes-display-inline">Federal research</header> 
<subsection id="H8B9A1A84A531429289F7F2DBF11E0276" commented="no" display-inline="no-display-inline"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, in coordination with the Director of the National Institutes of Health and the heads of other relevant Federal agencies, shall submit to the Caucus on International Narcotics Control, the Committee on the Judiciary, and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce and the Committee on the Judiciary of the House of Representatives a report on—</text> <paragraph id="H6AF66347958E4348B26EB32E3D074F1C" commented="no" display-inline="no-display-inline"><enum>(1)</enum><text display-inline="yes-display-inline">the potential therapeutic effects of cannabidiol or marijuana on serious medical conditions, including intractable epilepsy;</text></paragraph> 
<paragraph id="HE55481E2236E4F13BD94E27B438C89C3" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">the potential effects of marijuana, including—</text> <subparagraph id="H5FC74A41968F484B8FB40D087ACC6B5C" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">the effect of increasing delta-9-tetrahydrocannabinol levels on the human body and developing adolescent brains; and</text></subparagraph> 
<subparagraph id="H60A4F610001742B099AF66A555A26CC6" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">the effect of various delta-9-tetrahydrocannabinol levels on cognitive abilities, such as those that are required to operate motor vehicles or other heavy equipment; and</text></subparagraph></paragraph> <paragraph id="H48490DF7E956455C980E69456CA7D29B" commented="no" display-inline="no-display-inline"><enum>(3)</enum><text display-inline="yes-display-inline">the barriers associated with researching marijuana or cannabidiol in States that have legalized the use of such substances, which shall include—</text> 
<subparagraph id="H4DABE6419D9843878F0A0442703906AB" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text display-inline="yes-display-inline">recommendations as to how such barriers might be overcome, including whether public-private partnerships or Federal-State research partnerships may or should be implemented to provide researchers with access to additional strains of marijuana and cannabidiol; and</text></subparagraph> <subparagraph id="HD937DD23873E4F939E0A41E4BF7115D2" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">recommendations as to what safeguards must be in place to verify—</text> 
<clause id="HD422319BF87A40F39BD3032D911C962A" commented="no" display-inline="no-display-inline"><enum>(i)</enum><text display-inline="yes-display-inline">the levels of tetrahydrocannabinol, cannabidiol, or other cannabinoids contained in products obtained from such States is accurate; and</text></clause> <clause id="HA073BE357FF44DB183B76BFAC434960E" commented="no" display-inline="no-display-inline"><enum>(ii)</enum><text display-inline="yes-display-inline">that such products do not contain harmful or toxic components.</text></clause></subparagraph></paragraph></subsection> 
<subsection id="H85E97AD900D642B685D86966C2B07C1E" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header display-inline="yes-display-inline">Activities</header><text display-inline="yes-display-inline">To the extent practicable, the Secretary of Health and Human Services, either directly or through awarding grants, contacts, or cooperative agreements, shall expand and coordinate the activities of the National Institutes of Health and other relevant Federal agencies to better determine the effects of cannabidiol and marijuana, as outlined in the report submitted under paragraphs (1) and (2) of subsection (a).</text></subsection></section></title> </legis-body> <attestation><attestation-group><role>Speaker of the House of Representatives.</role></attestation-group><attestation-group><role>Vice President of the United States and President of the Senate.</role></attestation-group></attestation> </bill> 

